CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

Bibliographic Details
Main Authors:	Guido Gini, Alice Di Rocco, Luca Nassi, Annalisa Arcari, Maria Chiara Tisi, Giacomo Loseto, Attilio Olivieri, Massimo Gentile, Ombretta Annibali, Maria Giuseppina Cabras, Annalisa Chiappella, Chiara Rusconi, Andrés José María Ferreri, Monica Balzarotti
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-11-01
Series:	Frontiers in Oncology
Subjects:	diffuse large B cell lymphoma (DLBCL) central nervous system involvement survey risk assessment prophylaxis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.730194/full

Similar Items

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
by: Maria Chiara Tisi, et al.
Published: (2019-12-01)

Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial
by: Michele Clerico, et al.
Published: (2024-07-01)

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
by: M. Novo, et al.
Published: (2022-06-01)

Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
by: Alessandra Tucci, et al.
Published: (2022-11-01)

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin’s lymphoma involving the mediastinum
by: Andrea Riccardo Filippi, et al.
Published: (2020-03-01)

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi
by: Michele Merli, et al.
Published: (2014-03-01)

Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
by: Alberto Bavieri, et al.
Published: (2024-12-01)

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
by: Manuel Gotti, et al.
Published: (2023-04-01)

P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.
by: M. Ladetto, et al.
Published: (2022-06-01)

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
by: Francesco Zaja, et al.
Published: (2017-05-01)

Fertility preservation and monitoring in adult patients diagnosed with lymphoma: consensus-based practical recommendations by the Fondazione Italiana Linfomi & Società Italiana della Riproduzione Umana
by: Carla Minoia, et al.
Published: (2023-09-01)

P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
by: B. Alessandria, et al.
Published: (2022-06-01)

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi
by: Sergio Storti, et al.
Published: (2018-08-01)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
by: Annalisa Chiappella, et al.
Published: (2013-11-01)

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
by: Gloria Margiotta-Casaluci, et al.
Published: (2023-03-01)

Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi
by: Stefano Luminari, et al.
Published: (2016-02-01)

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
by: Riccardo Bomben, et al.
Published: (2018-05-01)

The Tumor Microenvironment of DLBCL in the Computational Era
by: Giuseppina Opinto, et al.
Published: (2020-03-01)

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
by: Stefano Sacchi, et al.
Published: (2016-05-01)

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)

P1256: A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY
by: D. Drandi, et al.
Published: (2022-06-01)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
by: Chiara Rusconi, et al.
Published: (2022-10-01)

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
by: Barbara Mantoan, et al.
Published: (2021-10-01)

Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature
by: N G GABEEVA, et al.
Published: (2018-07-01)

Chlamydia psittaci E LINFOMI DEGLI ANNESSI OCULARI: IMPLICAZIONI TERAPEUTICHE
by: J. Andrés, et al.
Published: (2005-09-01)

A Rare Case of Primary Bone Follicular Lymphoma with Multiple Osteolytic Lesions: A Case Report and Review of the Literature
by: Chiara Togni, et al.
Published: (2024-09-01)

Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report
by: Shruthi, et al.
Published: (2023-01-01)

LINFOMI E VIRUS HCV
by: M. Spinosa, et al.
Published: (2005-09-01)

CD30 Expression and Its Correlation with Clinicopathologic Features in Indonesian Diffuse Large B-Cell Lymphoma
by: Maria Reynelda Santoso, et al.
Published: (2020-09-01)

Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs
by: Gohar S. Manzar, et al.
Published: (2024-09-01)

Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications
by: Epameinondas Koumpis, et al.
Published: (2024-07-01)

Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients
by: Zhenbang Ye, et al.
Published: (2024-07-01)

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
by: Mark J. Bishton, et al.
Published: (2023-02-01)

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma
by: Changying Wang, et al.
Published: (2023-03-01)

Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation
by: Smeeta Gejendra, et al.
Published: (2015-11-01)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
by: Susanna Tokola, et al.
Published: (2020-03-01)

Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma
by: Jili Deng, et al.
Published: (2022-12-01)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
by: Xuemei Wu, et al.
Published: (2023-05-01)

CD24 is a surrogate for ‘immune‐cold’ phenotype in aggressive large B‐cell lymphoma
by: Morihiro Higashi, et al.
Published: (2022-07-01)

LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme
by: Le Ge, et al.
Published: (2020-05-01)